transmembrane protein 94Genealiases: ERMA · IDDCDF · KIAA0195
Q-omics provides the consensus-scored TMEM94 profile across patient tissues and cancer cell-line models. TMEM94 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TMEM94 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, TMEM94 RNA expression shows 20,341 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where TMEM94 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM94 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM94 survival associations across molecular data types. TMEM94 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM94 RNA expression–survival associations across cancer types. High TMEM94 expression shows unfavorable associations in ACC and LIHC, but favorable associations in KIRC, LUAD, READ and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for TMEM94 RNA expression.
This table summarizes TMEM94 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TMEM94. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM94 shows lower tumor expression in KICH and higher tumor expression in LIHC, HNSC, BLCA, STAD and KIRP. The LIHC box plot shows higher TMEM94 RNA expression in tumor versus normal tissue (log2 FC = +1.422, t-test p < 0.001).
This table shows molecular features associated with TMEM94 in patient tissues and cancer cell lines. In patient samples, TMEM94 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM94 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and UPPER_AERODIGESTIVE_TRACT.
